We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In a recent decision, the Patented Medicine Prices Review Board (PMPRB) has ruled that it has jurisdiction over products sold in the U.S., but imported into Canada under Health Canada's Special Access Program (SAP
